A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of
elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or
NASH (nonalcoholic steatohepatitis)